Then why did ZACKS lower their rating to a sell today? I have paid for my Zacks account for years and they are right many more times than they are wrong. I'am still going to hold but I will keep a watch on.
The reason this stock will not likely run up from here, at least until earnings are reported, is because approvals are just the first step. Booking the revenues and cost controls are very improtant as well. March 15 earnings will be a pivotal report as we can see the affect marketing costs including the hiring of contract employees will affect their earnings. It is very expensive to launch a drug and their will be very little sales of Uceris to book this quarter. If they can manage those costs well, I think there will be huge upside for the rest of the year.
I agree, you are my analyst and I am your analyst. Kitty has been analyzing this company since mid-2010.
Everything is improving and more on the way.
Rhuconest registration application will be filed later this year. VPHM's Cinryze sells $300 million per year for prophylaxis of HAE. Rhuconest should be a great addition for SNTS around early 2014 for acute treatment of HAE attacks.